Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

B-cell Malignancies × tirabrutinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2 Recurrence 1 Lymphoma, Non-Hodgkin 1 Leukemia, B-Cell 1 B-cell Malignancies 1

Interventions

zanubrutinib 3 tislelizumab 1 tirabrutinib 1 obinutuzumab 1 itacitinib 1 idelalisib 1 Voriconazole 1 Influenza Vaccines 1 INCB039110 1 Fluconazole 1 Diltiazem 1 Clarithromycin 1 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02457598 2025-06-17

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Gilead Sciences

Phase 1 Terminated

203 enrolled 43 charts

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡